Mr. Speaker, the Standing Committee on Industry extensively reviewed the drug patents issue and recommended in its April report that the 20-year life of patents remain unchanged. However, we know that there are tensions within the cabinet on this issue.
My question is directed to the Minister of Industry. Can the government indicate if its position is the one taken by the Minister of Health, who is in favour of easing the rules, or the one taken by the Minister of Industry, who is comfortable with the 20-year period?